Letters

Inhaled insulin: Concerns remain

BMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7552.1273-e (Published 25 May 2006) Cite this as: BMJ 2006;332:1273
  1. Niamh M Martin, specialist registrar (n.martin@imperial.ac.uk),
  2. Karim Meeran, consultant
  1. Metabolic Medicine Unit, Hammersmith Hospital, London W12 0HS
  2. Metabolic Medicine Unit, Hammersmith Hospital, London W12 0HS

    EDITOR—Morton-Eggleston and Barrett conclude that the adverse effects of inhaled insulin are not clinically worrisome.1 Insulin is a potent mitogen and growth factor in the lung, leading to concerns that repeated inhaled delivery of insulin results in supraphysiological alveolar insulin deposition which …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe